mTOR抑制剂依维莫司在肾细胞癌治疗中的应用  

Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma

作　　者：张琳袁 张明[2] 达骏[2] ZHANG Lin-yuan;ZHANG Ming;DA Jun(Clinical Medicine, Undergraduate of Grade 2012, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China)

机构地区：[1]上海交通大学医学院,上海200025 [2]上海交通大学医学院附属第九人民医院泌尿外科,上海200011

出　　处：《上海交通大学学报（医学版）》2016年第12期1812-1816,共5页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：通过介绍PI3K/AKT/mTOR信号通路及其在肾癌中的作用，探讨mTOR抑制剂依维莫司在肾癌靶向治疗中分别作为一线、二线和序贯治疗的效果，简述其不良反应。依维莫司单用作为一线治疗效果欠佳，支持肾癌治疗指南中依维莫司用于晚期肾癌抗血管生成酪氨酸激酶抑制剂治疗失败的二线治疗策略。依维莫司联合其他药物用于一线治疗的方案值得进一步研究。依维莫司治疗总体耐受性较好，但其引起的3～4级不良反应比率较高仍是亟需解决的问题。The efficacy of mTOR inhibitor everolimus for targeted first-line, second-line, and sequential treatments of renal cell carcinoma is investigatedand adverse reactions are summarized through introducing the PI3K/AKT/mTOR signaling pathways and their roles in renal cell carcinoma. It has beenshown that everolimus alone has poor efficacy in first-line treatment, supporting the strategy mentioned in renal cell carcinoma treatment guidelines thateverolimus can be used in second-line treatment after unsuccessful treatment with anti-angiogenic tyrosine kinase inhibitors. First-line treatment witheverolimus plus other drugs requires further investigation. Everolimus has generally good tolerance, but the problem of high rate of grade 3-4 adversereactions still needs to be solved.

关 键 词：PI3K/AKT/mTOR信号通路 肾癌 靶向治疗 依维莫司 临床疗效 

分 类 号：R737.11[医药卫生—肿瘤]